MCID: TMP003
MIFTS: 66

Temporal Arteritis

Categories: Rare diseases, Cardiovascular diseases, Nephrological diseases, Bone diseases, Neuronal diseases, Muscle diseases, Oral diseases

Aliases & Classifications for Temporal Arteritis

MalaCards integrated aliases for Temporal Arteritis:

Name: Temporal Arteritis 57 12 53 54 59 15 73
Polymyalgia Rheumatica 57 12 76 59 37 55 43 44 15 73
Giant Cell Arteritis 57 12 76 53 54 59 37 43 44 73
Cranial Arteritis 57 53 54 73
Rhizomelic Pseudopolyarthritis 59 73
Horton Disease 76 59
Gca 57 53
Horton's Giant Cell Arteritis 53
Horton's Temporal Arteritis 53
Giant Cell Arteritis; Gca 57
Arteritis Temporalis 53
Arteritis Cranialis 53
Horton's Arteritis 53
Horton’s Syndrome 53
Horton's Disease 12
Horton’s Disease 53

Characteristics:

Orphanet epidemiological data:

59
giant cell arteritis
Inheritance: Multigenic/multifactorial; Prevalence: 1-9/100000 (Germany),1-5/10000 (United Kingdom),1-5/10000 (Europe); Age of onset: Adult; Age of death: normal life expectancy;

OMIM:

57
Inheritance:
autosomal dominant


HPO:

32
temporal arteritis:
Inheritance autosomal dominant inheritance


Classifications:



Summaries for Temporal Arteritis

MedlinePlus : 43 Giant cell arteritis is a disorder that causes inflammation of your arteries, usually in the scalp, neck, and arms. It narrows the arteries, which keeps blood from flowing well. Giant cell arteritis often occurs with another disorder called polymyalgia rheumatica. Both are more common in women than in men. They almost always affect people over the age of 50. Early symptoms of giant cell arteritis resemble the flu: fatigue, loss of appetite, and fever. Other symptoms include Headaches Pain and tenderness over the temples Double vision or visual loss, dizziness Problems with coordination and balance Pain in your jaw and tongue Your doctor will make the diagnosis based on your medical history, symptoms, and a physical exam. There is no single test to diagnose giant cell arteritis, but you may have tests that measure inflammation. Treatment is usually with corticosteroids. Early treatment is important; otherwise there is a risk of permanent vision loss or stroke. However, when properly treated, giant cell arteritis rarely comes back. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

MalaCards based summary : Temporal Arteritis, also known as polymyalgia rheumatica, is related to retinal vasculitis and vasculitis, and has symptoms including back pain, exanthema and muscle cramp. An important gene associated with Temporal Arteritis is CRP (C-Reactive Protein), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Prednisone and Anti-Inflammatory Agents have been mentioned in the context of this disorder. Affiliated tissues include testes, tongue and skin, and related phenotypes are ptosis and nystagmus

NIH Rare Diseases : 53 Giant cell arteritis (GCA) is a form of vasculitis, a group of disorders that cause inflammation of blood vessels. GCA most commonly affects the arteries of the head (especially the temporal arteries, located on each side of the head), but other arteries can also become inflamed. The inflammation causes the arteries to narrow, resulting in poor blood flow. Signs and symptoms may include a throbbing headache on one side of the head or the back of the head, tenderness of the scalp, various symptoms that feel like the flu, and/or problems with eyesight. The cause of GCA is still being studied, but it is thought to involve the immune system mistakenly attacking the artery walls. Several genetic and environmental factors may increase a person's risk to develop GCA. Complications of GCA may include permanent vision loss or a stroke, so treatment is important and may include corticosteroids and/or other medications that suppress the immune system. GCA may develop with or after another inflammatory disorder known as polymyalgia rheumatica. 

NINDS : 54 Vasculitis is inflammation of blood vessels, which includes the veins, arteries, and capillaries. It occurs when the immune system mistakenly attacks a blood vessel. Vasculitis can also be caused by other immune system disease, an allergic reaction to medicines or toxins, and by certain blood cancers that trigger an immune system reaction. The resulting reduced blood flow can permanently damage the brain, spinal cord, peripheral nervous system, and other organs and tissue. Some forms of vasculitis affect a particular organ, whie others may affect many organs at the same time. Symptoms include headaches (especially a headache that doesn’t go away), fever, weight loss, confusion or forgetfulness leading to dementia, swelling of the brain, pain, vision problems, trouble speaking or understanding, muscle weakness and paralysis, and seizures. Some of the better understood vasculitis syndromes are temporal arteritis (also called giant cell arteritis or cranial arteritis--a chronic inflammatory disorder of large blood vessels) and Takayasu’s disease, which affects larger aortas and may cause stoke.

Wikipedia : 76 Giant-cell arteritis (GCA), also called temporal arteritis, is an inflammatory disease of blood vessels.... more...

Description from OMIM: 187360

Related Diseases for Temporal Arteritis

Diseases in the Temporal Arteritis family:

Juvenile Temporal Arteritis

Diseases related to Temporal Arteritis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 311)
# Related Disease Score Top Affiliating Genes
1 retinal vasculitis 32.7 APOH CCL2
2 vasculitis 30.7 APOH CCL2 CD40LG CRP
3 aortitis 30.4 CRP SMUG1
4 polyarteritis nodosa 30.3 APOH CRP IL6
5 purpura 30.3 APOH CD40LG CRP
6 endocarditis 30.3 APOH CRP IL6
7 chlamydia 30.1 CD40LG CRP IFNG IL6
8 infective endocarditis 29.9 APOH CRP IL6
9 retinal vein occlusion 29.8 APOH CCL2 IL6
10 arteriosclerosis 29.7 CCL2 CRP IL6
11 myeloma, multiple 29.6 CD40LG CRP IL6 SMUG1
12 periodontitis 29.5 CCL2 CRP IFNG IL6
13 vascular disease 29.5 APOH CCL2 CRP IL6
14 hypersensitivity vasculitis 29.4 CD40LG CRP
15 wegener granulomatosis 29.4 CRP IFNG IL6 PTPN22
16 pneumonia 28.6 CCL2 CCL5 CD40LG CRP IL6
17 interstitial lung disease 28.4 CCL2 CCL5 IFNG IL6
18 arthritis 28.2 CCL2 HLA-DRB1 IFNG IL1RN IL6 PTPN22
19 myocardial infarction 28.1 CCL2 CCL5 CD40LG CRP IL6
20 rheumatoid arthritis 25.8 CCL2 CCL5 CD40LG CRP HLA-DRB1 IFNG
21 juvenile temporal arteritis 12.6
22 nonarteritic anterior ischemic optic neuropathy 11.5
23 vasculitis syndromes of the central and peripheral nervous systems 11.1
24 acalculous cholecystitis 10.9 CD40LG CRP
25 mononeuritis multiplex 10.8 CD40LG CRP
26 borderline leprosy 10.8 APOH CD40LG
27 viral exanthem 10.8 APOH CD40LG
28 cat-scratch disease 10.8 CD40LG IFNG
29 livedoid vasculopathy 10.8 APOH CD40LG
30 erythema infectiosum 10.8 APOH CD40LG
31 sporotrichosis 10.8 CD40LG IFNG
32 acute maxillary sinusitis 10.8 CD40LG CRP
33 ovarian squamous cell carcinoma 10.7 CRP SMUG1
34 berylliosis 10.7 HLA-DRB1 IFNG
35 cardiovascular syphilis 10.7 CD40LG SMUG1
36 japanese spotted fever 10.7 CD40LG CRP
37 neuronitis 10.7 CD40LG TNFRSF10A
38 chronic beryllium disease 10.7 HLA-DRB1 IFNG
39 rheumatoid factor-negative juvenile idiopathic arthritis 10.7 HLA-DRB1 PTPN22
40 autoimmune addison disease 10.7 HLA-DRB1 PTPN22
41 pelvic inflammatory disease 10.6 CCL2 CD40LG CRP
42 gastrointestinal tuberculosis 10.6 IFNG SMUG1
43 pleurisy 10.6 CCL2 CRP IFNG
44 tolosa-hunt syndrome 10.6 CD40LG SMUG1
45 cold agglutinin disease 10.6 CRP IL6
46 systemic scleroderma 10.6 CD40LG CRP IFNG
47 geniculate herpes zoster 10.6 CD40LG TNFRSF10A
48 suppurative otitis media 10.6 CD40LG CRP
49 mumps 10.5 CD40LG HLA-DRB1 IFNG
50 syphilis 10.5 APOH CD40LG HLA-DRB1

Comorbidity relations with Temporal Arteritis via Phenotypic Disease Network (PDN): (show all 24)


Active Peptic Ulcer Disease Acute Cystitis
Aortic Valve Disease 1 Bronchitis
Cerebral Arteritis Chronic Myocardial Ischemia
Conn's Syndrome Deficiency Anemia
Esophagitis Familial Atrial Fibrillation
Heart Disease Hypertension, Essential
Hypothyroidism Intermediate Coronary Syndrome
Iron Deficiency Anemia Ischemic Heart Disease
Mitral Valve Disease Nonarteritic Anterior Ischemic Optic Neuropathy
Optic Neuritis Osteoporosis
Polymyositis Premature Ovarian Failure 7
Rheumatoid Arthritis Transient Cerebral Ischemia

Graphical network of the top 20 diseases related to Temporal Arteritis:



Diseases related to Temporal Arteritis

Symptoms & Phenotypes for Temporal Arteritis

Symptoms via clinical synopsis from OMIM:

57
Eyes:
blindness
retinal arteritis

Lab:
elevated sedimentation rate

Vascular:
temporal arteritis
giant cell arteritis
polymyalgia rheumatica (pmr)

Misc:
response to adrenal glucocorticoids


Clinical features from OMIM:

187360

Human phenotypes related to Temporal Arteritis:

59 32 (show top 50) (show all 59)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 ptosis 59 32 occasional (7.5%) Occasional (29-5%) HP:0000508
2 nystagmus 59 32 occasional (7.5%) Occasional (29-5%) HP:0000639
3 diplopia 59 32 occasional (7.5%) Occasional (29-5%) HP:0000651
4 depressivity 59 32 frequent (33%) Frequent (79-30%) HP:0000716
5 hyperhidrosis 59 32 occasional (7.5%) Occasional (29-5%) HP:0000975
6 ataxia 59 32 occasional (7.5%) Occasional (29-5%) HP:0001251
7 muscle weakness 59 32 occasional (7.5%) Occasional (29-5%) HP:0001324
8 sudden cardiac death 59 32 occasional (7.5%) Occasional (29-5%) HP:0001645
9 arthritis 59 32 frequent (33%) Frequent (79-30%) HP:0001369
10 joint stiffness 59 32 hallmark (90%) Very frequent (99-80%) HP:0001387
11 visual impairment 59 32 frequent (33%) Frequent (79-30%) HP:0000505
12 optic atrophy 59 32 occasional (7.5%) Occasional (29-5%) HP:0000648
13 renal insufficiency 59 32 occasional (7.5%) Occasional (29-5%) HP:0000083
14 fever 59 32 hallmark (90%) Very frequent (99-80%) HP:0001945
15 fatigue 59 32 hallmark (90%) Very frequent (99-80%) HP:0012378
16 arthralgia 59 32 occasional (7.5%) Occasional (29-5%) HP:0002829
17 abdominal pain 59 32 occasional (7.5%) Occasional (29-5%) HP:0002027
18 weight loss 59 32 hallmark (90%) Very frequent (99-80%) HP:0001824
19 abnormality of the pleura 59 32 occasional (7.5%) Occasional (29-5%) HP:0002103
20 alopecia 59 32 frequent (33%) Frequent (79-30%) HP:0001596
21 aortic dissection 59 32 occasional (7.5%) Occasional (29-5%) HP:0002647
22 skin ulcer 59 32 occasional (7.5%) Occasional (29-5%) HP:0200042
23 ophthalmoparesis 59 32 frequent (33%) Frequent (79-30%) HP:0000597
24 visual field defect 59 32 occasional (7.5%) Occasional (29-5%) HP:0001123
25 anorexia 59 32 hallmark (90%) Very frequent (99-80%) HP:0002039
26 cerebral ischemia 59 32 hallmark (90%) Very frequent (99-80%) HP:0002637
27 myalgia 59 32 occasional (7.5%) Occasional (29-5%) HP:0003326
28 paresthesia 59 32 occasional (7.5%) Occasional (29-5%) HP:0003401
29 amaurosis fugax 59 32 occasional (7.5%) Occasional (29-5%) HP:0100576
30 hematuria 59 32 occasional (7.5%) Occasional (29-5%) HP:0000790
31 diabetes insipidus 59 32 occasional (7.5%) Occasional (29-5%) HP:0000873
32 vertigo 59 32 occasional (7.5%) Occasional (29-5%) HP:0002321
33 visual loss 59 32 occasional (7.5%) Occasional (29-5%) HP:0000572
34 conductive hearing impairment 59 32 occasional (7.5%) Occasional (29-5%) HP:0000405
35 epistaxis 59 32 occasional (7.5%) Occasional (29-5%) HP:0000421
36 pericarditis 59 32 occasional (7.5%) Occasional (29-5%) HP:0001701
37 recurrent pharyngitis 59 32 occasional (7.5%) Occasional (29-5%) HP:0100776
38 meningitis 59 32 occasional (7.5%) Occasional (29-5%) HP:0001287
39 cough 59 32 occasional (7.5%) Occasional (29-5%) HP:0012735
40 vasculitis 59 32 hallmark (90%) Very frequent (99-80%) HP:0002633
41 hepatic failure 59 32 occasional (7.5%) Occasional (29-5%) HP:0001399
42 arterial thrombosis 59 32 occasional (7.5%) Occasional (29-5%) HP:0004420
43 headache 59 32 hallmark (90%) Very frequent (99-80%) HP:0002315
44 mediastinal lymphadenopathy 59 32 occasional (7.5%) Occasional (29-5%) HP:0100721
45 gastrointestinal infarctions 59 32 occasional (7.5%) Occasional (29-5%) HP:0005244
46 gangrene 59 32 occasional (7.5%) Occasional (29-5%) HP:0100758
47 glossitis 59 32 occasional (7.5%) Occasional (29-5%) HP:0000206
48 elevated erythrocyte sedimentation rate 59 32 frequent (33%) Frequent (79-30%) HP:0003565
49 double outlet right ventricle with subpulmonary ventricular septal defect without pulmonary stenosis 59 32 occasional (7.5%) Occasional (29-5%) HP:0011658
50 abdominal aortic aneurysm 59 32 occasional (7.5%) Occasional (29-5%) HP:0005112

UMLS symptoms related to Temporal Arteritis:


back pain, exanthema, muscle cramp, muscle rigidity, muscle spasticity, pruritus, sciatica, muscle weakness, myalgia, angina pectoris, chest pain, edema

MGI Mouse Phenotypes related to Temporal Arteritis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 9.28 CCL2 CCL5 CD40LG CRP IFNG IL1RN

Drugs & Therapeutics for Temporal Arteritis

Drugs for Temporal Arteritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 100)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 53-03-2 5865
2 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
3 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
4 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
5 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
6 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
7 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
8 Omega 3 Fatty Acid Nutraceutical Phase 4,Not Applicable
9
Infliximab Approved Phase 3,Phase 2 170277-31-3
10
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3,Phase 3,Not Applicable 83-43-2 6741
11
Prednisolone Approved, Vet_approved Phase 2, Phase 3,Phase 3,Not Applicable 50-24-8 5755
12
Hydroxychloroquine Approved Phase 3 118-42-3 3652
13
Adalimumab Approved Phase 3 331731-18-1 16219006
14
Alendronate Approved Phase 3 121268-17-5, 66376-36-1 2088
15
Etanercept Approved, Investigational Phase 3 185243-69-0
16
Methotrexate Approved Phase 3,Phase 2 1959-05-2, 59-05-2 126941
17
Abatacept Approved Phase 3,Phase 2 332348-12-6 10237
18
Alfacalcidol Approved, Nutraceutical Phase 3 41294-56-8 5282181
19
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3,Not Applicable 1406-16-2
20
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 59-30-3 6037
21
leucovorin Approved, Nutraceutical Phase 3,Phase 2 58-05-9 143 6006
22 Antirheumatic Agents Phase 3,Phase 2,Not Applicable
23 Dermatologic Agents Phase 3,Phase 2,Phase 1,Not Applicable
24 Gastrointestinal Agents Phase 3,Phase 2,Not Applicable
25 Anti-Infective Agents Phase 3,Not Applicable
26 Antiemetics Phase 2, Phase 3,Not Applicable
27 Autonomic Agents Phase 2, Phase 3,Not Applicable
28 Methylprednisolone acetate Phase 2, Phase 3,Phase 3,Not Applicable
29 Methylprednisolone Hemisuccinate Phase 2, Phase 3,Phase 3,Not Applicable
30 Neuroprotective Agents Phase 2, Phase 3,Not Applicable
31 Peripheral Nervous System Agents Phase 2, Phase 3,Phase 3,Not Applicable
32 Prednisolone acetate Phase 2, Phase 3,Phase 3,Not Applicable
33 Prednisolone hemisuccinate Phase 2, Phase 3,Phase 3,Not Applicable
34 Prednisolone phosphate Phase 2, Phase 3,Phase 3,Not Applicable
35 Protective Agents Phase 2, Phase 3,Not Applicable
36 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Not Applicable
37 Pharmaceutical Solutions Phase 3,Not Applicable
38 Antimalarials Phase 3
39 Antiparasitic Agents Phase 3
40 Antiprotozoal Agents Phase 3
41 Bone Density Conservation Agents Phase 3,Not Applicable
42 Hydroxycholecalciferols Phase 3
43 Micronutrients Phase 3,Not Applicable
44 Trace Elements Phase 3,Not Applicable
45 Vitamins Phase 3,Not Applicable
46 Analgesics Phase 3
47 Analgesics, Non-Narcotic Phase 3
48 Anti-Inflammatory Agents, Non-Steroidal Phase 3
49 Antimetabolites Phase 3,Phase 2,Not Applicable
50 Antimetabolites, Antineoplastic Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 74)
# Name Status NCT ID Phase Drugs
1 Steroids Pharmacokinetics and the Response to Prednisone Therapy in Giant Cell Arteritis Unknown status NCT01400464 Phase 4 Prednisone therapy and pharmacokinetic
2 Short Term Efficacy of a Starting Dose of 12.5 mg of Prednisone in Polymyalgia Rheumatica Patients Completed NCT01169597 Phase 4 prednisone
3 Tocilizumab Dose-tapering and Interruption in Patients With Giant Cell Arteritis Achieving the Clinical Remission. Recruiting NCT03244709 Phase 4 Tocilizumab
4 Trial to Study the Effects of Supplementary Omega-3 on Serum C-Reactive Protein Levels Terminated NCT00578578 Phase 4
5 Infliximab Therapy in Patients With Refractory Polymyalgia Rheumatica Unknown status NCT01423591 Phase 3 infliximab;inactive powder
6 Hydroxychloroquine in Giant Cell Arteritis Completed NCT00430807 Phase 3 hydroxychloroquine/placebo
7 HECTHOR: Humira to Spare Steroids in Giant Cell Arteritis Completed NCT00305539 Phase 3 adalimumab;placebo
8 Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol. Completed NCT00138983 Phase 3 Alendronate versus alfacalcidol (1-alpha OH vitamin D)
9 Timed Release Tablet Prednisone in Polymyalgia Rheumatica Completed NCT00836810 Phase 2, Phase 3 Timed Release Tablet Prednisone;Prednisolone
10 Etanercept Treatment in the Early Course of Polymyalgia Rheumatica Completed NCT00524381 Phase 3 Etanercept (Enbrel);Sodium chloride (placebo)
11 An Extension Study to Evaluate Long-Term Safety of Subcutaneous (SC) Tocilizumab in Participants With Giant Cell Arteritis (GCA) Recruiting NCT03202368 Phase 3 Tocilizumab
12 A Study to Evaluate the Efficacy of Tocilizumab as a Remission-Induction and Glucocorticoid-Sparing Regimen in Subjects With New-Onset Polymyalgia Rheumatica (PMR- SPARE) Recruiting NCT03263715 Phase 3 Tocilizumab Prefilled Syringe [Actemra];Placebos;Glucocorticoids
13 Safety and Efficacy of tocilizuMAb Versus Placebo in Polymyalgia rHeumatica With glucocORticoid dEpendence SEMAPHORE Recruiting NCT02908217 Phase 3 Tocilizumab;Placebo
14 An Efficacy and Safety Study of Tocilizumab (RoActemra/Actemra) in Participants With Giant Cell Arteritis (GCA) Active, not recruiting NCT01791153 Phase 3 Tocilizumab;Prednisone;Tocilizumab Placebo;Prednisone Placebo;Corticosteroids;Methotrexate
15 Giant Cell Arteritis and Anakinra Trial Not yet recruiting NCT02902731 Phase 3 PLACEBO;ANAKINRA
16 Treatment With Leflunomide in Patients With Polymyalgia Rheumatica Not yet recruiting NCT03576794 Phase 3 Leflunomide 20 mg;Prednisolone
17 Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis Terminated NCT02531633 Phase 3 Sirukumab;Placebo to match sirukumab;Prednisone;Placebo to match prednisone
18 A Study Assessing the Efficacy and Safety of Lodotra® Compared to Prednisone IR in Subjects Suffering From PMR Terminated NCT01821040 Phase 3 Lodotra®;Prednisone IR (immediate release)
19 A Study to Evaluate Efficacy and Safety of Subcutaneous Abatacept With Steroid Treatment Compared to Steroid Treatment Alone in Adults With Giant Cell Arteritis (GCA) Withdrawn NCT03192969 Phase 3 Abatacept;Glucocorticoid Treatment
20 Efficacy and Safety Study of Sirukumab in Subjects With Polymyalgia Rheumatica Withdrawn NCT02899026 Phase 3 Sirukumab;Placebo to match sirukumab;Prednisone /Prednisone placebo
21 Tocilizumab for Patients With Giant Cell Arteritis Completed NCT01450137 Phase 2 Tocilizumab + Glucocorticoids (GCs);Placebo + Glucocorticoids (GCs)
22 Abatacept for Treating Adults With Giant Cell Arteritis and Takayasu's Arteritis Completed NCT00556439 Phase 2 Abatacept;Placebo
23 Evaluation of Tocilizumab as an add-on Therapy to Corticoids in Giant Cell Arteritis: Proof of Concept Study. Completed NCT01910038 Phase 2 corticoids+ tocilizumab 8mg/Kg/4 weeks
24 Phase II Randomized Study of Glucocorticoids With or Without Methotrexate for Treatment of Giant Cell Arteritis Completed NCT00004686 Phase 2 methotrexate;prednisone
25 Tocilizumab Effect iN pOlymyalgia Rheumatica Completed NCT01713842 Phase 2 TCZ
26 Study of Tocilizumab to Treat Polymyalgia Rheumatica Completed NCT01396317 Phase 2 Tocilizumab
27 Safety Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle to Treat Uveitis Completed NCT01789320 Phase 1, Phase 2 triamcinolone acetonide (Triesence®)
28 Ustekinumab for the Treatment of Giant Cell Arteritis Recruiting NCT02955147 Phase 1, Phase 2 Ustekinumab;Prednisone
29 Baricitinib in Relapsing Giant Cell Arteritis Recruiting NCT03026504 Phase 2 Baricitinib
30 Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma Active, not recruiting NCT01740297 Phase 1, Phase 2 Talimogene laherparepvec;Ipilimumab
31 Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis Not yet recruiting NCT03482479 Phase 2 Naltrexone Hydrochloride
32 A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Giant Cell Arteritis Terminated NCT00076726 Phase 2 Infliximab
33 Delayed Release Prednisone in PMR Terminated NCT02702778 Phase 2 Delayed-Release (DR) Prednisone;Immediate Release (IR) Prednisone
34 A 3-arm Proof of Concept Study of AIN457, ACZ885 or Corticosteroids in Patients With Polymyalgia Rheumatica Terminated NCT01364389 Phase 2 AIN457;ACZ885;Prednisone;Placebo
35 MRI Superficial Temporal Artery Completed NCT00188448 Phase 1
36 Diagnostic Study of Temporal Arteritis Unknown status NCT01130857
37 Giant Cell Arteritis: Improving Use of Ultrasound Evaluation Unknown status NCT02523625
38 Sensitivity and Specificity of Color Doppler Directed Temporal Artery Biopsy as Compared to Standard Random Biopsy in the Diagnosis of Temporal Arteritis Unknown status NCT00361192 Early Phase 1
39 Study of Phenotypic and Functional Characteristics of Regulatory T Lymphocytes in Horton's Disease Unknown status NCT02857192 Not Applicable
40 Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases Unknown status NCT00006055 Not Applicable anti-thymocyte globulin;cyclophosphamide;cyclosporine;filgrastim;methylprednisolone;prednisone
41 Study of the T CD8 Immune Response in Horton's Disease Unknown status NCT02158208
42 Efficacy of Micro-Pulse Steroid Therapy as Induction Therapy in Patients With Polymyalgia Rheumatica Unknown status NCT00982332 Not Applicable Betamethasone;isotonic sodium chloride solution (placebo)
43 Quantitative and Functional Study of TH17 Lymphocytes in Horton's Disease (HD) Unknown status NCT02065297
44 FDG Uptake in Large-Vessel Giant Cell Arteritis After Short-term, High-Dose Steroid Treatment Completed NCT03285945 PET3;PET10
45 Diagnostic Accuracy of FDG PET/CT of Cranial Arteries in GCA Completed NCT03409913
46 Temporal Artery Biopsy vs ULtrasound in Diagnosis of GCA (TABUL) Completed NCT00974883
47 Carotid Artery Neovascularization in Takayasu's and Giant Cell Arteritis Completed NCT01795456
48 Educational Needs of Patients With Systemic Vasculitis Completed NCT02190929
49 Journey of Patients With Vasculitis From First Symptom to Diagnosis Completed NCT03410290
50 Impact of Vasculitis on Employment and Income Completed NCT02476292

Search NIH Clinical Center for Temporal Arteritis

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: polymyalgia rheumatica

Genetic Tests for Temporal Arteritis

Anatomical Context for Temporal Arteritis

MalaCards organs/tissues related to Temporal Arteritis:

41
Testes, Tongue, Skin, Brain, Eye, Spinal Cord, Bone

Publications for Temporal Arteritis

Articles related to Temporal Arteritis:

(show top 50) (show all 1208)
# Title Authors Year
1
Central retinal vein occlusion in temporal arteritis: red sign or red herring? ( 29361164 )
2018
2
Fusion of positron emission tomography/computed tomography with magnetic resonance imaging reveals hamstring peritendonitis in polymyalgia rheumatica. ( 29121248 )
2018
3
Ultrasonography and magnetic resonance imaging changes in patients with polymyalgia rheumatica treated by tocilizumab. ( 29370856 )
2018
4
Intravascular Large B-Cell Lymphoma Mimicking Temporal Arteritis. ( 29854538 )
2018
5
Assessing polymyalgia rheumatica activity when C-reactive protein is unavailable or uninterpretable. ( 29346621 )
2018
6
The potential for dual pathology in temporal arteritis. ( 29186538 )
2018
7
Association between characteristics of pain and stiffness and the functional status of patients with incident polymyalgia rheumatica from primary care. ( 28634698 )
2017
8
Diagnosis of polymyalgia rheumatica usually means a favourable outcome for your patient. ( 28948949 )
2017
9
Multiple Tumor Induction after Treatment of Temporal Arteritis with Prednisone. ( 29515399 )
2017
10
Proliferative Synovitis of the Shoulder Bursae is a Key Feature for Discriminating Elderly Onset Rheumatoid Arthritis Mimicking Polymyalgia Rheumatica From Polymyalgia Rheumatica. ( 29242702 )
2017
11
Clinical correlation of biopsy results in patients with temporal arteritis. ( 29451658 )
2017
12
The acupuncture therapeutic approach in temporal arteritis vasculitis: A case report. ( 29436372 )
2017
13
Studies on the Histopathology of Temporal Arteritis. ( 28275606 )
2017
14
Serum immunoglobulin G4 in giant cell arteritis and polymyalgia rheumatica. ( 27974093 )
2017
15
Stroke and temporal arteritis: A study of 6 cases. ( 28869044 )
2017
16
Amyloidosis Mimicking Temporal Arteritis in Multiple Myeloma. ( 29157426 )
2017
17
[Ischaemic necrosis of the tongue due to temporal arteritis]. ( 28473023 )
2017
18
Not Every Case of Temporal Arteritis Is Giant Cell Arteritis. Microscopic Polyangiitis Involving the Temporal Artery: A Case Report and Review of the Literature. ( 29293114 )
2017
19
Giant Cell (Temporal) Arteritis with Persistent Bilateral Sensorineural Hearing Loss - A Likely Consequence of Delayed Institution of Glucocorticoid Therapy. ( 29186088 )
2017
20
[Polymyalgia rheumatica: new developments and challenges]. ( 29192568 )
2017
21
The OMERACT Core Domain Set for Outcome Measures for Clinical Trials in Polymyalgia Rheumatica. ( 28765246 )
2017
22
Identification of herpes zoster associated temporal arteritis among cases of giant cell arteritis. ( 29294312 )
2017
23
Gene expression profiling in patients with polymyalgia rheumatica before and after symptom-abolishing glucocorticoid treatment. ( 28784116 )
2017
24
Lethal Subarachnoid and Intracerebral Haemorrhage Associated with Temporal Arteritis. A Case Report. ( 29967889 )
2017
25
Metaplastic ossification of the temporal artery with osteoclast-like giant cells: a mimicker of giant cell (temporal) arteritis. ( 28315516 )
2017
26
[Polymyalgia rheumatica: diagnostic and therapeutic issues of an apparently straightforward disease.] ( 28643813 )
2017
27
Giant cell arteritis and polymyalgia rheumatica: current challenges and opportunities. ( 28905861 )
2017
28
Clinical Value of FDG-PET/CT for the Evaluation of Rheumatic Diseases: Rheumatoid Arthritis, Polymyalgia Rheumatica, and Relapsing Polychondritis. ( 28583280 )
2017
29
Is PET/CT essential in the diagnosis and follow-up of temporal arteritis? ( 28899801 )
2017
30
Polymyalgia rheumatica and cancer risk: the importance of the diagnostic set. ( 27843375 )
2016
31
Assessment of the New 2012 EULAR/ACR Clinical Classification Criteria for Polymyalgia Rheumatica: A Prospective Multicenter Study. ( 26834222 )
2016
32
Efficacy of first-line tocilizumab therapy in early polymyalgia rheumatica: a prospective longitudinal study. ( 26929219 )
2016
33
When a temporal artery biopsy reveals a diagnosis other than temporal arteritis: eosinophilic granulomatosis with polyangiitis. ( 27316282 )
2016
34
Rapid and Sustained Response to Tocilizumab in Patients with Polymyalgia Rheumatica Resistant or Intolerant to Glucocorticoids: A Multicenter Open-label Study. ( 26724323 )
2016
35
A Prospective Open Label Phase IIa Trial of Tocilizumab In the Treatment of Polymyalgia Rheumatica. ( 27159185 )
2016
36
The Temporal Arteritis Proforma: Should cough be included? ( 27592336 )
2016
37
A Case of Frontal Fibrosing Alopecia in a Patient with Primary Biliary Cirrhosis and Polymyalgia Rheumatica. ( 27843932 )
2016
38
Association of Remitting Seronegative Symmetrical Synovitis with Pitting Edema, Polymyalgia Rheumatica, and Adenocarcinoma of the Prostate. ( 26839040 )
2016
39
Temporal Arteritis With Arteritic Anterior Ischemic Optic Neuropathy is Bilateral Until Proven Otherwise: Response. ( 27855129 )
2016
40
Juvenile temporal arteritis with eosinophilia associated with systemic sclerosis. ( 27401371 )
2016
41
Does Viking ancestry influence the distribution of polymyalgia rheumatica and giant cell arteritis in Poland? ( 27088874 )
2016
42
Temporal arteritis with erythrocyte sedimentation rate <50 mm/h: a clinical reminder. ( 26966355 )
2016
43
Is All Inflammation within Temporal Artery Biopsies Temporal Arteritis? ( 27445262 )
2016
44
VZV, temporal arteritis, and clinical practice: False positive immunohistochemical detection due to antibody cross-reactivity. ( 26688577 )
2016
45
Polymyalgia Rheumatica and Giant Cell Arteritis: A Review Article. ( 27156261 )
2016
46
Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) in Polymyalgia Rheumatica. ( 27342326 )
2016
47
Patient-reported outcomes in trials of patients with polymyalgia rheumatica: a systematic literature review. ( 26769433 )
2016
48
Extracranial cutaneous manifestation of temporal arteritis--a case of erythematous plaques on the legs. ( 26713645 )
2016
49
Recent advances in the diagnosis and treatment of polymyalgia rheumatica. ( 27079756 )
2016
50
Associations between polymyalgia rheumatica and giant cell arteritis and 12 cardiovascular diseases. ( 26786818 )
2016

Variations for Temporal Arteritis

Expression for Temporal Arteritis

Search GEO for disease gene expression data for Temporal Arteritis.

Pathways for Temporal Arteritis

Pathways related to Temporal Arteritis according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.77 CCL2 CCL5 CD40LG CRP HLA-DRB1 IFNG
2
Show member pathways
13.46 CCL2 CCL5 CD40LG IFNG IL1RN IL6
3
Show member pathways
13.11 CCL2 CCL5 CD40LG HLA-DRB1 IFNG IL1RN
4
Show member pathways
13.07 CCL2 CCL5 CD40LG IL6 PTPN22 TNFRSF10A
5
Show member pathways
12.53 CCL2 CCL5 HLA-DRB1 IFNG IL6 TNFRSF10A
6 12.15 CCL2 CCL5 CD40LG IFNG IL1RN PTPN22
7
Show member pathways
11.84 CCL2 CCL5 IFNG IL6 TNFRSF10A
8 11.8 CCL2 IFNG IL6
9 11.75 CCL2 CCL5 IL6
10 11.49 CCL2 CCL5 IL6
11
Show member pathways
11.47 CD40LG IFNG IL6
12
Show member pathways
11.43 CCL2 CCL5 CRP IFNG IL6 SERPINA3
13 11.31 CCL2 CCL5 IL1RN IL6
14 11.31 CCL2 CCL5 HLA-DRB1 IFNG IL6
15 11.25 CCL2 CD40LG IFNG IL6
16 11.06 HLA-DRB1 IFNG IL6
17 10.85 CCL2 SERPINA3
18 10.84 CRP IL6

GO Terms for Temporal Arteritis

Cellular components related to Temporal Arteritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.61 APOH CCL2 CCL5 CD40LG CRP IFNG
2 extracellular space GO:0005615 9.28 APOH CCL2 CCL5 CD40LG CRP IFNG

Biological processes related to Temporal Arteritis according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.84 CRP IFNG IL6 PTPN22
2 cytokine-mediated signaling pathway GO:0019221 9.81 CCL2 CCL5 IL1RN IL6
3 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.65 CCL5 IFNG IL6
4 positive regulation of T cell proliferation GO:0042102 9.63 CCL5 CD40LG IL6
5 regulation of signaling receptor activity GO:0010469 9.63 CCL2 CCL5 CD40LG IFNG IL1RN IL6
6 humoral immune response GO:0006959 9.61 CCL2 IFNG IL6
7 immune response GO:0006955 9.56 CCL2 CCL5 CD40LG HLA-DRB1 IFNG IL1RN
8 positive regulation of endothelial cell apoptotic process GO:2000353 9.55 CCL2 CD40LG
9 monocyte chemotaxis GO:0002548 9.54 CCL2 CCL5 IL6
10 macrophage chemotaxis GO:0048246 9.52 CCL2 CCL5
11 acute-phase response GO:0006953 9.5 CRP IL6 SERPINA3
12 negative regulation of lipid storage GO:0010888 9.49 CRP IL6
13 lipopolysaccharide-mediated signaling pathway GO:0031663 9.43 CCL2 CCL5 PTPN22
14 negative regulation of interleukin-1-mediated signaling pathway GO:2000660 9.4 IL1RN IL6
15 inflammatory response GO:0006954 9.23 CCL2 CCL5 CD40LG CRP IL1RN IL6

Molecular functions related to Temporal Arteritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.8 APOH CCL2 CCL5 CD40LG CDK9 CRP
2 cytokine activity GO:0005125 9.1 CCL2 CCL5 CD40LG IFNG IL1RN IL6

Sources for Temporal Arteritis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....